A Phase 1 interventional study of KL0011034 injection and Alfentanil Hydrochloride Injection in Chronic Pain, sponsored by The Third Xiangya Hospital of Central South University. Not yet recruiting. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.
Sponsored by The Third Xiangya Hospital of Central South University · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the drug-drug interaction between KL0011034 Injection and Alfentanil Hydrochloride Injection in participants with moderate-to-severe non-cancer chronic pain. The study consists of two parts. Part 1 is a single-center, randomized, open-label, parallel-design study to evaluate the safety, tolerability, and pharmacodynamics of the combination. Approximately 9 participants will be enrolled and randomized to one of three dose groups (n=3 per group). Part 2 is a single-center, randomized, open-label, three-sequence, three-period crossover study to evaluate the pharmacokinetic interaction, safety, tolerability, and pharmacodynamic effects. Approximately 18 participants will be enrolled and randomized to one of three sequences (n=6 per sequence), with a 3-day washout period between each period.
Study Design and Population:
This is a two-part, single-center, randomized, open-label study in participants with moderate-to-severe non-cancer chronic pain. Part 1 uses a parallel-group design, and Part 2 uses a three-sequence, three-period crossover design.
Part 1 (Safety, Tolerability, and Pharmacodynamics):
Approximately 9 participants will be randomized in a 1:1:1 ratio to one of three dose groups to receive a single combined dose of Alfentanil Hydrochloride Injection 5 μg/kg plus KL0011034 Injection at one of three dose levels (Group 1: 0.3 mg/kg; Group 2: 0.35 mg/kg; Group 3: 0.4 mg/kg). Pharmacodynamic and safety evaluations will be conducted, and participants will be discharged after the end-of-study examinations on Day 2 (D2). Based on the results from Part 1, the maximum dose of KL0011034 Injection among the three dose levels that is deemed safe and tolerable will be selected for use in Part 2.
Part 2 (Pharmacokinetic Interaction, Safety, Tolerability, and Pharmacodynamics):
Approximately 18 participants will be randomized in a 1:1:1 ratio to one of three sequences (A, B, or C), with 6 participants per sequence. Each participant will complete three open-label treatment periods (Day 1, Day 4, and Day 7), with a 3-day washout period between periods. The selected KL0011034 dose from Part 1 will be used in Part 2. Pharmacokinetic sampling, pharmacodynamic evaluations, and safety assessments will be performed during each period. Participants will be discharged after the end-of-study examinations on Day 8 (D8).
Sequence A: Period 1: KL0011034 Injection (selected dose); Period 2: Alfentanil Hydrochloride Injection 5 μg/kg; Period 3: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose).
Sequence B: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg; Period 2: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose); Period 3: KL0011034 Injection (selected dose).
Sequence C: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose); Period 2: KL0011034 Injection (selected dose); Period 3: Alfentanil Hydrochloride Injection 5 μg/kg.
3,227 studies on the registry are indexed under Chronic Pain; 729 are open to participants now.
This study's planned enrollment of 27 is below the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Browse Chronic Pain studies →The Third Xiangya Hospital of Central South University is the lead sponsor of 99 studies on the registry; 52 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.3 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.35 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Part 1: Participants receive a single dose of Alfentanil Hydrochloride Injection 5 μg/kg combined with KL0011034 Injection 0.4 mg/kg on Day 1. Safety, tolerability, and pharmacodynamic evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Part 2, Sequence A: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: KL0011034 Injection (selected dose from Part 1); Period 2: Alfentanil Hydrochloride Injection 5 μg/kg; Period 3: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1). Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Part 2, Sequence B: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg; Period 2: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1); Period 3: KL0011034 Injection (selected dose from Part 1). Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
Part 2, Sequence C: Participants receive three interventions across three periods (Day 1, Day 4, Day 7) with a 3-day washout between periods: Period 1: Alfentanil Hydrochloride Injection 5 μg/kg + KL0011034 Injection (selected dose from Part 1); Period 2: KL0011034 Injection (selected dose from Part 1); Period 3: Alfentanil Hydrochloride Injection 5 μg/kg. Pharmacokinetic, pharmacodynamic, and safety evaluations are conducted.
Drug: KL0011034 injection · Drug: Alfentanil Hydrochloride Injection
KL0011034 Injection is an investigational drug being studied for its analgesic properties in combination with alfentanil. It is administered via intravenous infusion. The dose levels evaluated are 0.3 mg/kg, 0.35 mg/kg, and 0.4 mg/kg in Part 1; the selected dose from Part 1 is used in Part 2.
Alfentanil Hydrochloride Injection is an opioid analgesic administered via intravenous bolus at a fixed dose of 5 μg/kg. It is used alone and in combination with KL0011034 Injection to evaluate drug-drug interaction.
Maximum Plasma Concentration (Cmax) of KL0011034
Cmax of KL0011034 in plasma, determined by non-compartmental analysis of concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Maximum Plasma Concentration (Cmax) of KL0011034 Metabolite A644S(A)-Z7
Cmax of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis of concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Maximum Plasma Concentration (Cmax) of Alfentanil
Cmax of Alfentanil in plasma, determined by non-compartmental analysis of concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of KL0011034
AUC0-t of KL0011034 in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of KL0011034 Metabolite A644S(A)-Z7
AUC0-t of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) of Alfentanil
AUC0-t of Alfentanil in plasma, determined by non-compartmental analysis using linear-log trapezoidal method.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034
AUC0-∞ of KL0011034 in plasma, calculated as AUC0-t + Clast/λz.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of KL0011034 Metabolite A644S(A)-Z7
AUC0-∞ of KL0011034 major metabolite A644S(A)-Z7 in plasma, calculated as AUC0-t + Clast/λz.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Area Under the Curve From Time Zero Extrapolated to Infinity (AUC0-∞) of Alfentanil
AUC0-∞ of Alfentanil in plasma, calculated as AUC0-t + Clast/λz.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing);immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours
Time to Maximum Plasma Concentration (Tmax) of KL0011034
Tmax of KL0011034 in plasma, determined directly from concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Time to Maximum Plasma Concentration (Tmax) of KL0011034 Metabolite A644S(A)-Z7
Tmax of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined directly from concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Time to Maximum Plasma Concentration (Tmax) of Alfentanil
Tmax of Alfentanil in plasma, determined directly from concentration-time data.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034
AUC0-24h of KL0011034 in plasma, determined by non-compartmental analysis.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of KL0011034 Metabolite A644S(A)-Z7
AUC0-24h of KL0011034 major metabolite A644S(A)-Z7 in plasma, determined by non-compartmental analysis.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Area Under the Curve From Time Zero to 24 Hours (AUC0-24h) of Alfentanil
AUC0-24h of Alfentanil in plasma, determined by non-compartmental analysis.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Elimination Half-Life (t1/2) of KL0011034
Elimination half-life (t1/2) of KL0011034 in plasma, calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase of the concentration-time curve. Unit: hours.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Elimination Half-Life (t1/2) of KL0011034 Metabolite A644S(A)-Z7
Elimination half-life (t1/2) of KL0011034 major metabolite A644S(A)-Z7 calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Elimination Half-Life (t1/2) of Alfentanil
Elimination half-life (t1/2) of Alfentanil calculated as ln(2)/λz, where λz is the terminal elimination rate constant determined by log-linear regression of the terminal phase.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Apparent Volume of Distribution (Vd) of KL0011034
Apparent volume of distribution (Vd) of KL0011034 calculated as Dose/(AUC0-∞ × λz).
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Apparent Volume of Distribution (Vd) of KL0011034 Metabolite A644S(A)-Z7
Apparent volume of distribution (Vd) of KL0011034 major metabolite A644S(A)-Z7 calculated as Dose/(AUC0-∞ × λz).
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Apparent Volume of Distribution (Vd) of Alfentanil
Apparent volume of distribution (Vd) of Alfentanil calculated as Dose/(AUC0-∞ × λz).
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Clearance (CL) of KL0011034
Total body clearance (CL) of KL0011034 calculated as Dose/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Clearance (CL) of KL0011034 Metabolite A644S(A)-Z7
Total body clearance (CL) of KL0011034 major metabolite A644S(A)-Z7 calculated as Dose/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Clearance (CL) of Alfentanil
Total body clearance (CL) of Alfentanil calculated as Dose/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Terminal Elimination Rate Constant (λz) of KL0011034
Terminal elimination rate constant (λz) of KL0011034 determined by log-linear regression of the terminal phase of the concentration-time curve.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Terminal Elimination Rate Constant (λz) of KL0011034 Metabolite A644S(A)-Z7
Terminal elimination rate constant (λz) of KL0011034 major metabolite A644S(A)-Z7 determined by log-linear regression of the terminal phase of the concentration-time curve.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Terminal Elimination Rate Constant (λz) of Alfentanil
Terminal elimination rate constant (λz) of Alfentanil determined by log-linear regression of the terminal phase of the concentration-time curve.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Mean Residence Time (MRT0-∞) of KL0011034
Mean residence time (MRT0-∞) of KL0011034 calculated as AUMC/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Mean Residence Time (MRT0-∞) of KL0011034 Metabolite A644S(A)-Z7
Mean residence time (MRT0-∞) of KL0011034 major metabolite A644S(A)-Z7 calculated as AUMC/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after infusion completion, and at 2, 5, 10, 15, 20, 30, 40, 50 minutes, and 1, 2, 4, 8, 12, 24 hours post-dose.
Mean Residence Time (MRT0-∞) of Alfentanil
Mean residence time (MRT0-∞) of Alfentanil calculated as AUMC/AUC0-∞.
Time frame: Part 2, each of the 3 treatment periods (Day 1, Day 4, Day 7): pre-dose (within 60 minutes before dosing); immediately after bolus completion, and at 1, 2, 3, 6, 11, 16, 21, 31, 41, 51, 61 minutes, and 2, 4, 8, 12, 24 hours post-dose.
Adverse Events and Serious Adverse Events
Incidence, severity, and causality of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) assessed by clinical observation and participant reporting.
Time frame: From signing of informed consent through study completion (up to Day 8 in Part 2); unresolved AEs followed every 2 weeks until resolution or stabilization, up to 28 days after last dose.
Vital Signs
Change from baseline in vital signs including blood pressure, pulse rate, respiratory rate, tympanic temperature, and oxygen saturation (SpO2).
Time frame: Part 2: Screening, Day -1, pre-dose on Day 3 and Day 6, pre-dose and at 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-dose in each treatment period (Day 1, Day 4, Day 7), and on Day 8 (end-of-study).
12-Lead Electrocardiogram Parameters
Change from baseline in 12-lead ECG parameters including heart rate, PR interval, QRS interval, and QT interval corrected using Fridericia's formula (QTcF).
Time frame: Part 2: Screening, Day -1, pre-dose on Day 3 and Day 6, pre-dose and at 30 minutes, 2 hours, 4 hours, 8 hours, 12 hours, and 24 hours post-dose in each treatment period (Day 1, Day 4, Day 7), and on Day 8 (end-of-study).
Physical Examination
Number of participants with clinically significant abnormalities in physical examination findings (skin, mucous membranes, lymph nodes, head, neck, chest, abdomen, spine/extremities, and nervous system), assessed by standard physical examination.
Time frame: Part 2: Screening, Day -1, and Day 8 (end-of-study).
Injection Site Reactions
Incidence and severity of injection site reactions (pain, tenderness, erythema, and induration/swelling), assessed by physical examination of the injection site using a standardized assessment scale. Severity graded as mild, moderate, or severe.
Time frame: Part 2: Pre-dose, immediately post-dose plus 30 seconds, and at 5 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, and 6 hours post-dose in each treatment period (Day 1, Day 4, and Day 7).
MOAA/S Sedation Score
Sedation level assessed using the Modified Observer's Assessment of Alertness/Sedation (MOAA/S) scale. Sedation onset defined as first MOAA/S score ≤4; recovery defined as MOAA/S score of 5 on 3 consecutive assessments.
Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) at 20 seconds, 40 seconds, 1 minute, 1 minute 20 seconds, 1 minute 40 seconds, 2 minutes, 2 minutes 20 seconds, 2 minutes 40 seconds, 3 minutes, and every minute thereafter until full recovery plus 10 minutes
Bispectral Index (BIS) Monitoring
Continuous BIS monitoring to assess depth of sedation/anesthesia. Anesthesia onset defined as first BIS value ≤60; duration of BIS between 40 and 60 is recorded.
Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) continuously until full recovery plus 10 minutes (recorded every 1 minute); up to 10 minutes post-dose for participants with no response.
Eyelash Reflex
Time to loss of eyelash reflex and time to recovery of eyelash reflex after study drug administration.
Time frame: Part 1 and Part 2: From pre-dose (-5 minutes) every 15 seconds until eyelash reflex recovery, with minimum assessment up to 2 minutes post-dose; for participants with no loss of reflex within 5 minutes post-dose, evaluated every 15 seconds up to 5 minute
Modified Aldrete Score for Discharge Readiness
Recovery assessed using the Modified Aldrete Score (evaluating activity, respiration, blood pressure, consciousness, and SpO2). Discharge criteria met when score ≥9 on 3 consecutive assessments.
Time frame: Part 1 and Part 2: From awakening, every 2 minutes until discharge criteria met (score ≥9 on 3 consecutive assessments); for participants with no response, starting at 10 minutes post-dose, every 2 minutes until discharge criteria met.
No study locations are listed for this record.
Plan to share: No — Individual participant data (IPD) will not be shared because this is a first-in-human or early-stage clinical trial involving a novel investigational drug. The data contain proprietary and confidential information that could compromise ongoing patent applications and future commercial development. Public data sharing at this stage may also violate our confidentiality agreements with the contract research organization (CRO) and regulatory authorities. Therefore, IPD sharing is not feasible until the drug receives market approval or the primary study results are fully published.
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.
Of 60 phase 1 interventional studies under Chronic Pain, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 56. This study's planned 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: KL0011034 · Alfentanil
The Third Xiangya Hospital of Central South University